Some nice share price action today. Mayne does appear to be in the 'undervalued' category IMO, part of this is due to poor current newsflow and some poor past decisions by the current team. Here's hoping they can deliver with E4, Nuvaring and continue to perform with their speciality products which have been a shining light for MYX over the last few years. As for most of their generics it's a tough gig so who knows, but I do see it as a big advantage that they have US manufacturing facilities especially with the status quo. Frustrating to be an investor here, of all the companies I have invested in this would have one of the poorest flow of investor releases (sensitive or not) that I have seen.
MYX Price at posting:
41.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)